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ABSTRACT
JAMES W. DELANCEY JR.: Creation of aTopoisomerase I-ECFPCell Line Using Recent
Knock-in Technology
(Under the direction of Assistant Professor Randy M.Wadkins)

Topoisomerase I(TOPI) is a nuclear enzyme that relieves torsional strain in DNA
during transcription or replication. Furthermore,TOPl is the target enzyme for
camptothecin antitumor drugs. Traditional immunohistochemical methods of studying
TOPl expression require cell fixation, which arrests cellular metabolism at an instance in
time. In efforts where TOPl studies rely on a function of time, cell fixation must occur at
many finite intervals so that researchers may take many data points to simulate a real
time assessment. To study TOPl activity continuously in cells, we are implementing
recent gene targeting/knock-in technology to create a natively expressed TOP1-EGFP
chimeric protein regulated by the TOPl endogenous promoter in an intact
medulloblastoma cell line. Portions of the TOPl gene have been cloned in bacterial
vectors. Vector sequences have been aligned with sequences from Genbank® assuring
integrity. Currently, knock-in gene constructions are being made as templates for future
knock-in and knockout events in the cell line to allow quick insertion of the
modifications of interest. ATOPl-EGFP cell line will provide stable expression of a
bioluminescentTOPl protein for collecting consistent, reproducible protein expression
data for evaluating the targeting and efficacy of new camptothecin antitumor drugs.
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INTRODUCTION
DNA is the genetic material for all living organisms on earth.* The DNA of human
cells is around 2 m long and stored within a spherical nucleus with the diameter of 10 pm.^
The storage and presentation of DNA to be used is a responsibility held by a group of
enzymes called topoisomerases.^ In human cells, the topological state of DNA is
determined by the number of turns a piece of DNA contains around its helical axis. When
a section of DNA is not being used for transcription, it must be stored in a supercoiled
topological state to allow for other cellular processes to occur (See Figure 1)."*

1.1 Human Topoisomerase I: Function and Structure
When a section of DNA is ready to be transcribed, there is a set of topoisomerases
to fill the need. Human topoisomerase I(TOPl)is a 91 kDa nuclear enzyme responsible
for "relaxing" supercoiled DNA. The process of relaxing supercoiled DNA is vital to cell
metabolism and is required during transcription, the synthesis of mRNA and rRNA, as
well as during chromosomal segregation in the S-phase of cellular growth. In human
cells, supercoiled DNA is"under-wound" or contains fewer turns around its helical axis
than it does at its lowest energy state.'* The proposed mechanism of relaxing supercoiled
DNA involves the residue Tyr-723 ofTOPI forming a phosphotyrosyl bond with the
backbone of a single strand of the double helix. The phosphotyrosyl bond conserves the
free energy of the bond removed from the backbone. This state is the DNA-TOPl covalent
intermediary complex. The DNAs double helix is then allowed to rotate freely around the
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opposing bond of the DNA double helix. The double helix rotates toward its lowest
energy state in accordEuice with the second law of thermodynamics. Afterward, the
phosphodiester bond from the backbone is replaced. The transcription machinery of the
cell is then allowed to proceed with transcription as well as the other vital processes of
metabolism.^'^

2

Figure 1: Illustration of Supercoiling. 1. No supercoiling. 2. One superhelical twist. This occurs when
superhelical tension is relieved by the DNA helix bending into a supercoiled loop. 3. Two superhelical
twists. This occurs when additional super helical tension is relieved by bending into a second supercoiled
loop.
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1.2 Antitumor Drugs Target Topoisomerase I
The abnormal metabolism of cancerous cells require higher levels of transcription
and replication. Due to increased metabolism, a greater quantity of the genomic DNA
must be relaxed to fulfill transcriptional demand. Hence, more TOP1 is synthesized to
relax more DNA, making it ready for transcription. This increase in TOP1 expression has
provided one means of targeting cancer cells.®
One class of antitumor drugs that target TOP1 are called camptothecins(CPT).
Specifically, this class of drugs targets the DNA-TOPl covalent intermediate formed
during theTOPl mechanism for relaxing supercoiled DNA (figure 2). These three
molecules, TOPl, CPT, DNA,create a ternary complex which stabilizes the DNA-TOPl
covalent intermediate. The stabilization of this complex prevents re-ligation of the DNA
backbone. The mechanism of cellular toxicity involves the collision of the DNA
replication fork and the ternary complex, which breaks the DNA stremd upon collision,
causing DNA damage. The accumulation of double-stranded breaks in genomic DNA
leads to cellular apoptosis."

4

Figure 2: DNA-TOPl-CPTTernary Structure Simulation. 1. Topoisomerase I- 2. DNA covalent
intermediate is stabilized by 3. camptothecin to make ternary structure. Components are sized and tilted
11.5

to improve visibility. This image is not drawn to scale.
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1.3 Difficulties of Traditional Topoisomerase I Expression Studies
There is much research being performed on CPT antitumor drugs. Hence,TOPl
expression studies are often called upon to assess the efficacy of these drugs. The
traditional method for TOPl expression studies includes immunohistochemical staining,
12

primarily, immunofluorescence staining.
Immunofluorescence staining is an accepted cmd routinely performed method for
diagnostic histopathology.^^ However, its use in protein expression studies is much more
tedious and requires a higher level of standardization to produce consistent results.
Secondly, immunofluorescence requires cell fixation. Cell fixation induces cross-links in
the cytoplasm between cellular proteins. These cross-links stop cellular metabolism at an
instant in time, such that the protein expressed at the time of fixation can be
assessed.

Therefore, protein expression studies that use immunofluorescence staining

techniques are limited in that they may only provide protein expression data at a fixed
14

point in time.

Conversely, drug targeting studies require protein expression and kinetics

data as a function of time. Hence, a high level of standardization must be observed in the
lab to produce a series of immunofluorescence protein expression assays. The level of
standardization required may be thought of as producing a series of Polaroid pictures that
must be significantly alike, such that if bound and flipped like a cartoon book, would
produce a motion picture with only the variables of time and protein expression.
This level of tedium has been absolved in bacterial models with the introduction of
EGFP is based on the cDNA of a naturally

enhanced green fluorescent protein (EGFP).

occurring bioluminescent protein from the genome of Aequorea victoria, a species of
jellyfish. EGFP has a major excitation point at a wavelength of 488 nm. EGFP's emission
peak of 509 nm is within the green portion of the visible spectrum. The cDNA of EGFP
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has been linked as a marker-gene to other genes under study to produce bioluminescent
chimeric proteins.’* These chimeric proteins can then be used in fluorescent microscopy
and real-time protein expression studies.
Plasmid-based transgene protein-expression methods have utilized this technology
in human cell lines.’'* Current methods of plasmid-based transgene protein expression
have induced protein overexpression in their producer cells, diminishing their long-term
stability. This effect is exaggerated when the foreign gene product produces negative
selective pressure, such as with TOPI. Traditionally, a high affmity promoter derived from
the cytomegalovirus(CMV)has been used in plasmid-based transgene protein expression.
However, protein overexpression and low stability are significant challenges with most
gene products expressed with the CMV promoter.’^
Christensen et al. have created a plasmid-based vector for the transgenic
expression of a TOPl-EGFP chimeric protein using the SV40 promoter, a promoter much
less active than the CMV promoter. This vector uses a novel method of expressing a single
bicistronic mRNA containing exons for both TOPl-EGFP and a gene for antibiotic
resistance. With this method, Mielke et al. have provided a novel method for real-time
protein expression assays ofTOPI (figure 3). However, the plasmid-based approach has
only created a semistable cell line. As with any plasmid-based vector, the trans-expression
of highly regulated proteins such as TOPI as a transgene, creates cellular stress by
disrupting the natural regulation of the gene of interest,

In this scenario, gene mis-

regulation creates selective pressure against the transgene and destabilization of the
producer cells. Secondly, gene mis-regulation may induce other unexpected changes in
cellular metabolism. Additionally, the inherent disadvantages of cancer cell lines, such as
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mismatch repair deficiency, aneuploidy, and altered metabolism, further exaggerate
IS

unpredictability and selective pressure against the transgenes.

As bioscience technology improves, new methods of gene assessment come to the
forefront. Technology similar to the gene knockout technologies used in mice have been
developed to give researchers the use of gene targeting via homologous recombination as a
19

method of assessing gene function in cultured cells.

Furthermore, similar gene targeting

technologies have been used in cultured human cells to produce knock-in alleles.
Advancements in genetic knock-in technologies have enabled researchers to create
20

chromosomal changes in cultured human cells.
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1.4 Advancements in Molecular Biology ImproveTopoisomerase I Expression
Studies
Further advancements in human gene targeting have produced the promoter-trap
targeting construct. This places a promoterless gene construct within the promoter-trap
region of an endogenous gene. This technology further increases the means of selecting
clones that are created via homologous recombination, reducing the number of clones
created by random integration.^^
Genetic knock-in technologies in cultured human cells have provided a means of
gene targeting, however traditional methods borrowed from gene targeting in mice have
proved inefficient in human cells. These traditional methods use lipofection and
electroporation technologies to introduce DNA to the cells. The inefficiency of these
methods may be explained by the lower rate at which exogenous DNA can be introduced
to human cells and the lower rate of homologous recombination due to a much larger
genome in human cells.^^
Topaloglu et al. have created a novel method to optimize the deUvery of intact
targeting DNA in cultured human cells. This method uses a recombinant adenoassociated virus-based vector(rAAV)in place of a plasmid-based vector. Topaloglu et al.
have seen a 25-fold increase in recombinant clones versus plasmid-based methods.
Additionally, their method uses a promoterless antibiotic resistance selection marker to
increase the proportion of clones by homologous recombination. A ere recombinase is
20

used later to introduce site-specific DNA breaks to remove the selection marker.
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1.5 The Benefits of aTopoisomerase l-EGFP Cell Line
In modem antitumor dmg research,TOPl expression studies are needed to test the
metabolic disruption caused by TOPl targeting drugs.^** Many labs that conduct this
research use immunostaining techniques to produce their data. Standardization of these
techniques vary between laboratories.'^ In this scenario, real-time TOPl expression
studies conducted from a stable cell line producing a native TOPl-EGFP chimeric protein
would provide more consistent and more reproducible data. Additionally, fewer resources
and less time would be involved in this step of drug research. Such TOPl protein
expression studies will allow for a better understanding of drugs that target TOPl and will
allow for the creation of new and better TOPl-targeting antitumor drugs.

1.6 Aims and Approach
The possibility of a stable TOPl-EGFP chimeric protein-producing cultured human
cell line would create a significant advantage in the study and production ofTOPl
targeting antitumor dmgs. A stable cell line would produce a means for real-time protein
expression studies in a long-term and stable format. Additionally, the cell line would
produce reproducible results with significantly less tedium than required for
immunofluorescence-based protein expression studies. Our lab aimed for a stable
endogenously regulated TOPl-EGFP chimeric protein-producing human cultured cell line.
To accomplish this, we have taken a several step approach to creating the genetic knock-in
based on a protocol by Rago et al (figure 4).'®
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1.7 Experimental Design
The cell line selected for this project was the DAOY human desmoplastic cerebellar
medulloblastoma cell line from ATCC. This cell line was chosen for its adherent
monolayer growth pattern and its cells' large, flat, polygonal shapes. The area of
homology selected for the homologous recombination event is nearly 2 kb and centers the
third exon ofTOPI (figure 4, step 1) to allow for 1 kb homology arms both upstream from
and downstream from the exon. The third exon ofTOPl was chosen rather than the first
exon to dismiss potential challenges caused by interference with upstream gene
regulation. pHAT is to be produced from subcloned PCR product created from the DAOY
cell line genomic DNA (figure 4, step 2). pHAT is to be checked against Genbank®
database records for integrity. pHAT is to be mutated by site-directed mutagenesis to
induce a restriction site within exon 3 such that the EGFP chimeric insertion may be
placed within that restriction site and in frame. EGFP is taken from aTOPl-EGFP
plasmid created by Mielke et al. containing EGFP linked TOPl cDNA. EGFP and the first
two exons ofTOPl were amplified by PCR from the plasmid and will be ligated inframe
with the third exon ofTOPl within pMHAT. This TOP1-EGFP chimeric insertion plasmid
will then be used to produce two homology arms, one containing the third exon ofTOPl
linked EGFP, and the other containing only part of the third intron ofTOPl. This PCR
product is created with restriction sites in its primers such that the synthetic exon
promoter trap antibiotic resistance selection marker is able to then be ligated between the
to homology arms. Additionally, the other side of each of homology arm contains a Notl
site to be ligated to the pAAV shuttle (figure 4, step 4). The pAAV shuttle, two other
plasmids and a viral titer-producing cell line are all supplied by Invitrogen™. These four
supplies are used per manufacturer's directions to produce a viral titer to infect the DAOY
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cell line. Upon infection, cells in which viral DNA was integrated into the genome via
homologous recombination will show antibiotic resistance (figure 4, step 5). A colony will
be made from a single antibiotic-resistant recombinant cell and verified for homologous
recombination via PCR and gene sequencing. A ere recombinase viral titer will then be
used to remove the SEPT element, effectively removing antibiotic resistance and restoring
function of the target gene (figure 4, step 6). New colonies will be made from single cells.
Those that exhibit antibody susceptibility will then be screened for SEPT cassette removal
via PCR, and subsequently, gene sequencing. Cells shown to contain the knock-in should
then be stable and produce a native TOP1-EGFP chimeric protein observable with
fluorescence microscopy. These cell lines may be used in TOPI protein expression and
kinetics studies.
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MATERIALS AND METHODS

2.1 Gel Electrophoresis
AJl DNA purification and PCR steps were followed with gel electrophoresis to
assure DNA quality and quantity. All plasmids used here contained one BamHI
restriction site in their MCS and were first linearized with BamHI prior to gel
electrophoresis.
The following components were mixed in a 1.5 ml microfiige tube and incubated
at 37°C for one hour:

Purified DNA (10 ng/pL)

10.0 pL

lOX NEBuffer 3

2.5 pL

BSA (10 ng/pL)

1.0 pL

BamHI(20,000 units/ml)

l.OpL

ddHaO

10.5 pL

Total reaction volume

25.0 pL

Gels were made from IX TAE buffer and a 0.8%(w/v) purified agarose (Fisher
Scientific, cat # BP160-100). Gels were 100 mL in total volume. Gels were poured 2/3 cm
thick in an 11 X 14 gel apparatus (Life Technologies Horizon® 11-14, Gibco, cat # 11068012). Buffer and purified agarose were mixed in a 250 mL Erlenmeyer flask and heated in
a microwave oven for 2 minutes. Agarose was mixed into solution on a stir plate and
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allowed to cool to 60°C at which point the solution was poured into the gel apparatus

mold.
There were two power supplies used, a VWR Scientific Products Accu Power,
PolyScience, model # 300) and a Bio-Rad PowerPac Basic. The gel electrophoresis
apparatus was filled with 900 mL IXTAE buffer. Voltage was applied to the gels at 1.9
V/cm for four hours or at 0.78 V/cm overnight.
All gels included a Quick-Load 2-log DNA ladder(New England BioLabs™, cat #
N0469S) as a DNA molecular weight marker with bromophenol blue tracking dye. All
samples were loaded with diluted 10 X Bluejuice Gel Loading Buffer (Invitrogen™, cat #
10816-015) diluted to 2X concentration. Gels were stained by submerging in 100 mL IX
SYBR Green II DNA stain (Invitrogen™, cat # S-7564)inTE buffer. Submerged gels were
shaken on a platform shaker(New Brunswick Scientific C2 Platform Shaker) at 72 RPMs
for 30 minutes. Gels were viewed on one of two CCTV UV trans-illumination systems
using their native software(KODAK Gel Logic 200 Imaging System and Bio-Rad Gel Doc).

2.2 Maintaining the DAOY Cell Line
Maintenance of DAOY cell line was based on the ATCC product information sheet
for the DAOY cell line. The cell line was maintained at 5% CO2 37“C in a Revco brand
humidity-controlled incubator. Cultures were kept in Fisher Scientific T-25 culture dishes.
Cell cultures were kept in complete growth medium made from Eagle's Minimum
Essential Medium (Catalog no. 30-2003) supplemented with a 10% final concentration of
fetal bovine serum (Hyclone, cat # BDH1135-4LG), and 2 mM L-glutamine (Gibco 25030081).
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Cells were split every seven days while semi-confluent and still in log phase. Cells
were examined for confluency with an Olympus CKX41 phase contrast inverted
microscope. To split the cells, a laminar flow hood (Labconco model 36288) was sanitized
with 70% EtOH. A 1 L bottle of Clorox Brand bleach stored within the laminar flow hood
was uncapped. Cell medium,stored at 4°C, was removed from the cooler and placed
within a 37°C water bath (Fisher Scientific Isotemp 205)for temperature equilibration.
Additionally, trypsin-EDTA,0.05% (Invitrogen™, cat # 25300-054), stored at -20°C, and
Hanks Buffered Saline Solution (HBSS, Fisher Scientific, cat # SH3003102), stored at 20°C,
were placed within the 37° water bath for temperature equilibration. After temperature
equilibration, all bottles were decontaminated by spraying with 70% EtOH inside the
laminar flow hood. Culture flasks were removed from the incubator, placed within the
flow hood, and decontaminated with 70% EtOH. Culture flask were uncapped and culture
medium aspirated with glass Pasteur pipette (Fisher Scientific, cat # 13-678-6 ). The cell
layer was rinsed with 10 mL of HBSS with an electric pipet aid(Drummond Portable Pipet
Aid)for 10 seconds and then aspirated. The cell layer was rinsed with 5 mL of 0.5%(w/v)
trypsin-0.53mM EDTA solution (Invitrogen™, cat # 25300-054)for five minutes and then
aspirated. The culture flask was inverted and tapped to loosen the cells from the bottom
of the culture flask. The cell layer was rinsed with 10 mL of cell medium. A 1 mL tip was
used with the electric pipet aid to force cells from bottom of culture flask into suspension.
Ten mL of medium was added to two new, sterile culture flasks and 1 mL of cell culture
suspension was added to each flask.
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2.3 PCR Primers
Primers were ordered from The Midland Certified Reagent Company, 3112-A West
Cuthbert Avenue, Midland,TX 79701. Primers were purified by TSP grade HPLC (figure
4, step 2).

Primer Sequences (all sequences are listed forward before reverse):
The following primers were designed for the amplification of the HAT from DAOY
genomic DNA:
5 * -GGAAGGAGCACGAGGGAAAC-3 *
5 * -CAAGTGATAAGAGATAAGTGAGGGATAG-3 *

The following primers are M13 sequencing primers and were designed for screening
colonies for insert size within the pCR-TOPO II vector via PCR:
5 *-GTAAAACGACGGCCAGT-3 *
5’-AACAGCTATGACCATG-3 *

The following primers were designed for conducting site-directed mutagenesis on pHAT
to create pMHAT.
5 * -TGGTTGCAGATTCTCATAAACACATCGATAAACACAAAGATCGAGAACAC-3'
5 * -GTGTTCTCGATCTTTGTGTTTATCGATGTGTTTATGAGAATCTGCAACCA-3 *

The following primers were designed for conducting site-directed mutagenesis on pMCEGFP-TIP to create a restriction site upstream from the EGFP gene.
5 * -GCGGCCGCGAATTAAGCTTCCATCGATAGCAAGGGCGAG-3 *
5 * -CTCGCCCTTGCTATCGATGGAAGCTTAATTCGCGGCCGC-3 *
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The following primers were designed for conducting site-directed mutagenesis on pMCEGFP-TIP to create a restriction site downstream from the EGFP gene.
5 * -TCATAAACACAAAGATAAACACATCGATCGAGAACACCGGCACAAAG-3

5 * -ctttgtgccggtgttctcgatcgatgtgtttatctttgtgtttatga-3

The following primers were designed for troubleshooting the PCR step of site-directed
mutagenesis for the location of the second mutation in pMC-EGFP-TIP. This pair of
primers does not contain mutations.
5 * -TCATAAACACAAAGATAAACACAAAGATCGAGAACACCGGCACAAAG-3 *
5 * -CTTTGTGCCGGTGTTCTCGATCTTTGTGTTTATCTTTGTGTTTATGA-3 *

2.4 TA Cloning
The Invitrogen™ TOPO TA Cloning® Kit (Invitrogen™, cat # K4520-01) protocol for
PCR product was the same for PCR products made with both enzymes. The protocol is
based on the recommended protocol by Invitrogen™ and is as follows:
Two LB plates were prepared containing 50 pg/mL ampicillin and incubated at
37°C. 1 L of LB medium was prepared containing 50 pg/mL ampicillin and stored at 4°C.

The following components were added to a 0.2 mL PCR microfuge tube:

ddH20

3.0 pL

PCR amplicon

1.0 pL

10 mM MgCh

1.0 pL

TOPO vector

1.0 pL

Total reaction volume

6.0 pL
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The reaction was gently mixed and incubated for five minutes at 20“C. The
reaction was placed on ice until ready for transformation.
Invitrogen™ brand One Shot® DH5a™-Tl® E. coli was used for the transformation.
A water bath (PolyScience model 1162) was set to 42°C to equilibrate for chemical
transformation of£ coli. SOC medium (included in the kit) was thawed to room
temperature. 40 pL of a 40 mg/mL X-gal in dimethylformamide solution ^d 40 pL of a
sterile-filtered 100 mM IPTG in ddHzO was spread on each plate, and the plates were
incubated at 37°C until used. A 37°C shaking incubator was prepared for use. One vial of
the DHSa'^' cells were thawed on ice for 30 minutes. Two microliters of theTOPO®
Cloning reaction was added to the vial of£ coli. The vial was thumped several times to
mix the cells. The vial was then incubated on ice for 30 minutes. The cells were heatshocked for 30 seconds at 42®C without shaking. Two hundred and fifty microliters of
room temperature SOC medium was added and the reaction was incubated on ice for 10
minutes. The contents of the tube was transferred to a sterile 15 mL polystyrene snap-cap
culture tube (Fisher Scientific, cat # 14-956-6A) and shaken in a 37°C incubator(New
Brunswick Scientific, model # C24)for one hour. After incubation, 50 pL of the
transformation was spread on one plate and 10 pL of the transformation was spread on the
other plate to assure evenly spread colonies. The plates were inverted and incubated at
37°C for 16 hours. Afterwards, 10 white colonies were selected and 10 sterile 15 mL
polystyrene snap-cap culture tubes were filled with 7 mL of LB medium containing 100
pg/mL ampicillin each. Each of the culture tubes were inoculated with one of the 10 white
colonies. Culture tubes caps were loosely secured to allow ventilation, and the tubes were
shaken for 16 hours at 37°C. Plasmid was purified with QIAGEN® Plasmid Midi Kit.
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Buffer P3 was pre-chilled to 4“C. Buffer P2 was warmed to 37”C. Cell cultures
were poured into individual 40 mL Nalgene® Oak Ridge polycarbonate centrifuge tubes
(Fisher Scientific, cat # 05-529C). The cells were harvested by centrifugation at 6000 x g
for 15 minutes at 4°C (Sorvall, RC-5B Plus). The supernatant was poured off and the
bacterial pellet was resuspended in 4 mL of Buffer Pi by pulse-vortexing. Four milliliters
Buffer P2 was added to the centrifuge tube. The suspension was mixed gently by
inverting the tube six times. The suspension was incubated for five minutes. Four
milliliters chilled Buffer P3 was added to the tube and the suspension was incubated on ice
for 15 minutes. The centrifuge tubes were centrifuged at 20,000 x g for 30 minutes at 4°C.
Supernatant containing plasmid DNA was removed promptly. The Supernatant was
centrifuged again at 20,000 x g for 15 minutes at 4“C to remove remaining precipitant.
Supernatant containing plasmid DNA was removed promptly. A QIAGEN-tip 100 was
equilibrated by applying 4 mL Buffer QBT to the colunrn and allowed to empty by gravity
flow. After column emptied, supernatant containing plasmid DNA was added to tube and
allowed to empty by gravity flow. The QIAGEN-tip was washed with 2 x 10 mL Buffer
QC. DNA was eluted with 5 mL Buffer QF. DNA was precipitated by adding 3.5 mL
room-temperature isopropanol to the eluted DNA. The solution was mixed and then
centrifuged at 15,000 x g for 30 minutes at 4"C. The supernatant was decanted. The DNA
pellet was washed with 2 mL of room temperature 70% EtOH and centrifuged at 15,000 x g
for 10 minutes. The supernatant was decanted. The pellet was air dried overnight and
redissolved in 200 pL of pH 8.0 TE buffer
DNA purity and concentration were determined via ultraviolet-visible
spectrophotometry (Shimadzu UV-160A) using a 1 cm path length and a 700|iL quartz
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cuvette. Baseline correction was performed with TE buffer. Absorption data were
collected for A260 and A280 to determine concentration of DNA and protein respectively.

2.4 Plasmid Sequencing
Plasmid sequencing was performed by SeqWright DNA Technology Services, 2575
West Bellfort, Suite 2001, Houston,TX 77054. DNA sequencing was performed in single
tube format from purified plasmid DNA and concentration was standardized to SeqWright
recommendation of 50 ng/pL. Sequencing chromatogram data were returned via e-mail.
Sequence data was analyzed and aligned with Genbank® using aT-Coffee software webapplet posted online by the European Bioinformatics Institute at
http://ww w.ebi.ac.uk/Tools/t-coffee/index.html

2.5 Buffers and Media
LB media: 10 g NaCl; 10 g tryptone; 5 g yeast extract; and ddH20 to a final volume of 1L;
adjust to pH 7.0 using NaOH or HCl; autoclave at 12rC for 15 minutes. Cool to 55°C
before adding antibiotic. Store at 4°C for a maximum of two weeks.
LB agar: 10 g NaCl; 10 g tryptone; 5 g yeast extract; 25 g agar; and ddH20 to a final
volume of 1 L; adjust to pH 7.0 using NaOH or HCl; autoclave at 121“C for 15 minutes.
Cool to 55°C in water bath before adding antibiotic. Pour into petri dishes and store at 4°C
for a maximum of two weeks,
ampicillin LB: add 100 mg ampicillin sodium salt to 1 L LB agar or 1L LB media. Store at
4°C.
TE buffer: 1.6 g tris-hydrochloride; 3.94 g tris-base; 0.475 g Na2EDTA; adjust to pH 8.
Store at room temperature.
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50X TAE buffer: 242

g tris-base; 57.1 mL glacial acetic acid; 37 g Na2EDTA. Store at room

temperature.

SOC medium: 0.584 g NaCl; 20 g tryptone; 5 g yeast extract; 0.186 g KCl; 0.952 g MgCb;
3.603 g glucose; and ddHoO to a final volume of 1 L; adjust to pH 7.0 using NaOH or HCl;
add 1.204 g MgSO^; autoclave at 121°C for 15 minutes. Store at 4°C.
Ampicillin stock: prepare a stack of 100 mg per milliliter of ampicillin sodium salt and
water; sterilize by filtration; store at -20°C. Use at a final concentration of 100 pg/mL.
X-gal stock: Dissolve X-gal in dimethylformamide at a concentration of40 pg/mL. Store
at -20°C. Spread 40 pL per LB plate.
IPTG stock: Dissolve IPTG in ddH20 at a concentration of lOOmM and filter sterilize.
Store at 4°C. Spread 40 pL per LB plate.
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RESULTS & DISCUSSION

3.1 DAOY Genomic DNA Extraction
The genomic DNA extraction method was based on QIAGEN® QIAamp® Blood
Mini Kit (cat # 51104). Cells were grown to semi-confluence inT-25 cell culture flask. The
cell layer was rinsed with 10 mL HBSS for 10 seconds and then aspirated. The cell layer
was rinsed with 5 mL trypsin-EDTA for five minutes and then aspirated. The cell culture
flask was inverted and tapped to loosen cells from the bottom of the culture flask. The cell
layer was rinsed with 2 mL of HBSS and pipetted up and down to force cells from the
bottom of the culture flask into suspension. Of the cell culture solution, 1.5 mL was added
to a 1.5 mL microfuge tube and spun at 6000 x g for one minute. The supernatant was
carefully removed from the microfuge tube. Two hundred microliters phosphate buffered
saline (PBS) was added to the 1.5 mL microfuge tube and the tube was vortexed to
suspend cells. A hemocytometer was used to determine a cell concentration of about 5 x
10* cells in 200 pL of PBS. Supplies from QIAGEN® QIAamp® DNA Blood Mini Kit were
used as follows: A dry heating block for 1.5 mL microfuge tubes was set to 56°C. Buffer
AE and proteinase K were equilibrated to room temperature. Buffer AL was warmed to
37°C in a water bath. Twenty microliters of proteinase K was pipetted into the bottom of a
1.5 mL microfuge tube. Two hundred microliters of the cell suspension was added to the
microfuge cube. Two hundred microliters of buffer AL was added to the sample and the
sample was mixed by pulse-vortexing for 15 seconds. To ensure efficient lysis, sample and
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buffer AL was mixed thoroughly to a homogeneous suspension. The suspension was
incubated at 56°C for 10 minutes. The microfuge tube was pulse-centrifuged to remove
condensation drops from the inside of the lid. Two hundred microliters of99% EtOH was
added to the sample and the sample was pulse-vortexed for 15 seconds. A QIAamp® spin
column was placed in a 2 mL collection tube and filled with the vortexed solution. The lid
of the spin column was closed and the spin column was centrifuged at 6000 x g for one
minute. The QIAamp® spin column was placed in a clean 2 mL collection tube and the
used collection tube in the filtrate was discarded. Five hundred microliters of Buffer AWl
was added to rinse the spin column. The spin column was centrifuged at 6000 x g for one
minute. The spin column was placed in a clean 2 mL collection tube. The previous 2 mL
collection tube and the filtrate was discarded. Five hundred microliters of Buffer AW2
was added to the spin column and centrifuged at 20,000 x g for three minutes. The
QIAamp® spin column was placed in a clean 1.5 mL microfuge tube. Two hundred
microliters of Buffer AE was added to the tube. The tube was incubated at room
temperature for one minute and then centrifuged at 6000 x g. DNA was stored in Buffer
AE at -20°C. (See figure 4, Step 1)

3.2 PCR Amplification of Homologous Region from Genomic DNA
Step 2 in figure 4 was accomplished via PCR. Several methods of PCR were used
to amplify the segment of genomic DNA for use as the HAT. Invitrogen™ Platinum® Taq
DNA Polymerase High Fidelity was used to produce the HAT amplicon the first time. The
protocol used for this enzyme is based on the manufacturer recommended protocol.
Invitrogen™ Platinum® Taq DNA Polymerase High Fidelity produced our desired amplicon
with the highest yield by the following protocol:
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The thermal cycler (Applied Biosystems GeneAmp 96 cat # 2700) was programmed
as follows:

Initial denaturation: 94“C for two minutes
30 cycles of:
Denature: 94°C for 60 seconds
Anneal: 52°C for 40 seconds
Extend: 72°C for four minutes
Final extension: 72°C for 30 minutes
Final hold: 4°C for oo

The following components were added to a 0.2 mL PCR microfuge tube:

ddHoO

18.5 pL

lOX High Fidehty buffer

2.5 pL

DMSO

0.5 pL

IM KCl

0.5 pL

10 mM dNTP mixture

0.5 pL

Primer 1 (100 ng/pL)

0.5 pL

Primer 2(100 ng/pL)

0.5 pL

Purified DNA (10 ng/pL)

2.0 pL

Platinum® Tag (5 units/ pL)

1.0 pL

Total reaction volume

26.5 pL

Invitrogen™ Platinum® Tag DNA Polymerase High Fidelity produced intermittent
results. However after making several adjustments to our PCR buffer, we were able to
produce an amplicon of the desired molecular weight (figure 5).
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Figure 5: Homology Arm Region Amplified from Genomic DNA with Taq Polymerase. Ml is a 2-log
ladder. Lanes 1 and 2 are simultaneous PCR reactions using Taq polymerase. The seventh band from the
top in lane Ml represents 2 kb — the size of the homology arm region amplicon. Note: Lanes 1 and 2 were
produced by simultaneous PCR reactions and contain DNA of the same molecular weight.
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PCR product was confirmed, the amplicon was cloned with the InvitrogenTOPO
TA Cloning kit and was sequenced. Upon sequencing, we discovered that the amplicon
contained too many random mutations to continue to the next step ofthe project (figure
6). Therefore, the need to re-create the HAT amplicon arose. We chose Finnzymes
Phusion^^' Flash High-Fidelity PCR Master Mix for its lower error rate and its ability to
produce a higher quality yield of our desired amplicon.
To produce the HAT amplicon, we set up a PCR reaction using Finnzymes
Phusion^'^ Flash High-Fidelity PCR Master Mix. The thermal cycler (Eppendorf**
Mastercycler Epgradient, model # 5341) was programmed as follows:

Initial denaturation: 98”C for 10 seconds
30 cycles of:
Denature: 98°C for one second
Anneal: 48“C for five seconds
Extend: 72°C for one minute
Final extension: 72°C for one minute
Final hold: 4°C for oo
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The following components were added to a 0.2 mL PCR microfuge tube:

ddH,0

23.5 pL

2X Phusion'“ Flash

25.0 pL

Primer 1 (100 ng/pL)

0.5 pL

Primer 2 (100 ng/pL)

0.5 pL

Purified DNA (10 ng/pL)

0.5 pL

Total reaction volume

50.0 pL

After PCR product was confirmed (figure 7), 10 units of Taq were added to the
reaction and the reaction was set at 72°C for five minutes to add adenine bases to the 3'
ends of the amplicon for compatibility with the TA cloning vector. The amphcon was then
cloned into the pCR-TOPO® II vector using the Invitrogen™TOPOTA Cloning kit. The
results from the cloning kit can be seen in figure 8. The plasmid was amplified and
sequenced. The sequence had incurred no mutations and was identical to the Genbank
database's sequence of the region.
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Figure 7:

Homology Arm Region Amplified from Genomic DNA with Phusion. Ml is a 2-log ladder.

Lanes 1 and 2 are simultaneous PCR reactions using Finnzymes Phusion'” Flash High-Fidelity DNA
Polymerase. The seventh band from the top in lane Ml represents 2 kb- the size of the homology arm
region amplicon.
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Figure 8; Homology Arm Template Subclone. Ml is a 2-log ladder. Lane 1 is Invitrogen pCR-TOPO II
vector without insert. The vector alone is 4 kb. Lane 2 is Invitrogen pCR-TOPO II vector with HAT insert.
The 4 kb vector plus the 2 kb insert make a total of 6 kb of DNA. The two plasmids are shown in three
bands. Arrows indicate linear DNA. The linear band of the vector alone (lane 1) is aligned with the fifth
band of the 2-log ladder, which represents 4 kb. The linear band of the HAT subclone (lane 2) is aligned
with the third band of the 2-log ladder and represents 6 kb.

32

3.3 Mutation of pHAT
The introduction of restriction sites into pHAT was performed using a Stratagene
Quickchange® XL site-directed mutagenesis kit (Stratagene, cat # 200516). The protocol
used is based on Stratagene recommendations and is as follows:
Two complementary oligonucleotides were designed to create the desired mutation
within pHAT The desired mutation created a restriction site for the BspDI(New England
BioLabs’“, cat # R0557S) restriction enzyme. The primers were designed by Quickchange®
Primer Design Program to contain the mutation £md to contain about 20 base pairs
flanking the mutation on either side. Primers were ordered from The Midland Certified
Reagent Company. Primers were purified by TSP grade HPLC.

The thermal cycler (Eppendorf** Mastercycler EPgradient) was programmed as follows:

Initial denaturation: 95°C for one minute
18 cycles of:
Denature: 95°C for 50 seconds
Anneal: 60°C for 50 seconds
Extend: 68“C for nine minutes
Final extension: 68°C for seven minijtes
Final hold: 4°C for oo
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The following components were added to a 0.2 mL PCR microfuge tube:

ddH.O

36.50 pL

lOX High Fidelity buffer

5.00 pL

DMSO

3.00 pL

10 mM dNTP mixture

1.00 pL

Primer 1 (100 ng/pL)

1.25 pL

Primer 2(100 ng/pL)

1.25 pL

Purified DNA (10 ng/pL)

2.00 pL

PfuTurbo^ (2.5 units/ pL)

1.00 pL

Total reaction volume

51.00 pL

After PCR amplification, 1 pL Dpnl is added to the PCR reaction to restrict
methylated template DNA. The reaction is incubated at 37°C for one hour.
See figure 9 for the PCR site directed mutagenesis results. The linear Dpnl treated
amplicon was cloned and the plasmid was amplified. After plasmid purification by the
Invitrogen kit, the plasmid was cut with the BspDI restriction enzyme (figure 10).
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Figure 9: Site-Di rected Mutagenesis of pH AT. Ml is a 2-log ladder. Lane 1 is pre-PCR reaction. Lane 2
is post-PCR reaction. Lane 3 is Dpnl restriction enzyme treated post-PCR reaction. Arrows indicate linear
product in lanes 2 and 3. Product in lane 3 is non-methylated and therefore not template DNA.
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Figure 10: pMHAT Cut with BspDI Site. Ml is a 2-Iog ladder. Lane 1 is uncut pMHAT. Lane 2 is
linearized pMHAT cut with mutation-induced restriction site. The linear band of lane 1 and the linearized
pMHAT in lane 2 align with the third band of the 2-log ladder which represents 6 kb.

36

3.4 Preparation of EGFP Insert
Our first method for excising the EGFP gene was to induce two site-directed
mutations to flank the EGFP gene both upstream and downstream. We were able to make
the first mutation, but after trying several polymerases and buffers, we could not produce
amplicon using the downstream primers for the other mutation. We ordered a new pair of
primers without mutations to see if we could simply amplify the plasmid from that
location. We were still unsuccessful. Therefore, we decided to excise the EGFP gene from
the pMC-EGFP-TIP plasmid, described by Christensen et al.,by amplifying the gene via
standard PCR technique.
The amplification of the EGFP insert was performed by creating two opposing
primers flanking the EGFP gene and the first two exons of the TOPI cDNA. These
primers were created to induce the mutation needed to insert the BspDI restriction site
into the appropriate locations surrounding the EGFP gene contained in the pMC-EGFPTIP plasmid. The PCR reaction was performed with Finnzymes Phusion™ High-Fidelity
PCR Master Mix with GC Buffer(New England BioLabs™, cat # F-532S). The protocol
used is based on the Finnzymes Phusion™ High-Fidelity PCR Master Mix with GC Buffer
protocol and is as follows:
Two opposing oligonucleotides were designed to flank the upstream side of the
EGFP gene on the downstream side of the second exon ofTOPI and to contain a
restriction site for the BspDI restriction enzyme (See Figure 11). The restriction sites were
placed such that the gene segment amplicon could be restricted and ligated in frame with
the third exon of linearized pMHAT. The primers Were designed by Quickchange® Primer
Design Program to contain the restriction site and to cont2un about 20 base pairs flanking
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the restriction site on either side. Primers were ordered from The Midland Certified
Reagent Company. Primers were purified by TSP grade HPLC.
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Figure 11; Creating EGFP Insert. This figure shows the process for making the EGFP knock-in insert for
placement in pMHAT.
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The thermal cycler (Eppendorf“ Mastercycler EPgradient) was programmed as follows:

Initial denaturation: 98°C for one minute
30 cycles of:
Denature: 98°C for 30 seconds
Anneal: 60°C for 50 seconds
Extend: 72°C for four minutes
Final extension: 72°C for 10 minutes
Final hold: 4°C for oo

The following components were added to a 0.2 mL PCR microfuge tube:

ddH20

20.00 pL

2X Phusion “ w/GC

25.00 pL

DMSO

1.50 pL

Primer 1 (100 ng/pL)

1.25 pL

Primer 2(100 ng/pL)

1.25 pL

Purified DNA (10 ng/pL)

1.00 pL

Total reaction volume

50.00 pL

Upon confirmation of this PCR reaction via gel electrophoresis (figure 12), DNA
polymerase enzyme was separated from the EGFP amplicon via PCI extraction. One
hundred and fifty microliters PCI solution and two 50 pL EGFP amplicon PCR reactions
were added to a clean 1.5 mL microfuge tube. The solution was pulse-vortexed and
centrifuged at 12,000 x g for one minute. Using a micropipette, the aqueous phase was
removed and mixed with an equal volume of chloroform in a clean 1.5 mL microfuge tube.
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The solution was pulse-vortexed and centrifuged at 12,000 x g for one minute. Using a
micropipette, the aqueous phase was removed and mixed with four volumes of
isopropanol in a clean 1.5 mL microfuge tube. The solution was pulse-vortexed and
centrifuged at 12,000 x g for 10 minutes. The supernatant was decanted from the DNA
pellet. The pellet was rinsed with 70% EtOH, pulse-vortexed, and centrifuged at 12,000 x g
for three minutes. The supernatant was decanted from the DNA pellet. The pellet was
allowed to dry for one hour, then redissolved in 100 pL TE buffer.
The following components were mixed in a 1.5 mL microfuge tube and incubated
for two hours at 37°C:

EGFP amplicon (50 ng/ pL)

45.00 pL

lOX NEBuffer 4

11.25 pL

BspDI (5,000 units/mL)

4.50 pL

ddHsO

51.75 pL

Total reaction volume

112.50 pL

Restriction enzyme was separated from DNA via PCI extraction. One hundred and
fifty microliters PCI solution was added to the 1.5 mL microfuge tube used for plasmid
linearization. Solution was pulse-vortexed and centrifuged at 12,000 x g for one minute.
Using a micropipette, the aqueous phase was removed and mixed with an equal volume of
chloroform in a clean 1.5 mL microfuge tube. The solution was pulse-vortexed and
centrifuged at 12,000 x g for one minute. Using a micropipette, the aqueous phase was
removed and mixed with four volumes of isopropanol in a clean 1.5 mL microfuge tube.
The solution was pulse-vortexed and centrifuged at 12,000 x g for 10 minutes. The
supernatant was decanted from the DNA pellet. The pellet was rinsed with 70% EtOH,
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pulse-vortexed, and centrifuged at 12,000 x g for three minutes. The supernatant was
decanted from the DNA pellet. The pellet was allowed to dry for one hour. The dry pellet
was redissolved in 45 pL TE buffer.

I
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Figure 12: EGFP Gene Amplicon. Ml is a 2-Iog ladder. Lane 1 is post-PCR EGFP gene amplicon which
will be inserted into pMHAT. The band in lane 1 aligns with the 10th band of the 2-log ladder which
represents 1 kb, the molecular weight of the EGFP gene.
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3.5 Preparation of HAT-EGFP Chimeric Insertion
Due to a need for more rapid plasmid purification, a new protocol for plasmid
purification was used for this step. The protocol is based on the Invitrogen”* PureLink’
Quick Plasmid Miniprep Kit (Invitrogen™, cat # K2100-11). A 50 mL aliquot ofTE buffer
was preheated to 70°C for elution step. Of an overnight cell culture, 1.5 mL was placed in
a 1.5 mL microfuge tube and centrifuged at 12,000 x g for two minutes(EppendorT*
microcentrifuge 5415D). The supernatant was decanted. The pellet was resuspended in
250 pL Buffer R3. The suspension was pulse-vortexed to homogeneity. Two hundred and
fifty microliters Lysis Buffer L7 was added to the suspension. The microfuge tube was
capped and inverted five times to mix. The tube was incubated for five minutes at room
temperature. Three hundred and fifty microliters Precipitation Buffer N4 was added to the
cells. The tube was capped and inverted five times to create a homogeneous suspension.
The mixture was centrifuged at 12,000 x g for 10 minutes at 20°C. The spin column was
placed in a collection tube. The supernatant was loaded into the spin column. The spin
column was centrifuged at 12,000 x g for one minute. The flow-through was discarded.
Five hundred microliters of Wash Buffer WlO was added to the column. The column was
centrifuged at 12,000 x g for one minute. The flow-through was discarded. Seven
hundred microliters of Wash Buffer W9 was added to the column. The column was
centrifuged at 12,000 x g for one minute. The flow-through was discarded. The spin
column was placed in the collection tube again and centrifuged at 12,000 x g for one
minute to reduce wash buffer residue. The flow-through and the collection tube was
discarded. The spin column was placed within a 1.5 mL microfuge tube and 45 pL of the
preheated TE buffer was added to the center of the column. The column was incubated
for one minute at room temperature. The tube was centrifuged at 12,000 x g for two
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minutes. The 1.5 mL microfuge tube contains the purified plasmid DNA,which was
confirmed via gel electrophoresis.
pMHAT was of sufficient purity for restriction after PureLink™ Quick Plasmid
Miniprep Kit. Plasmid linearization was based on a protocol provided by New England
BioLabs'“. The following components were mixed in a 1.5 mL microfuge tube and
incubated for two hours at 37°C:

Purified DNA (10 ng/pL)

45.00 pL

lOX NEBuffer 4

11.25 pL

BspDI (5,000 units/ml)

4.50 pL

ddHaO

51.75 pL

Total reaction volume

112.50 pL

Restriction enzyme was separated from DNA via phenol-chloroform (PCI)
extraction (Phenol/Chloroform/Isoamyl Alcohol Solution 25:24:1 Mixture,@ pH 8.0,
Fisher Scientific, cat # BP1752I-100). One hundred and fifty microliters PCI solution was
added to the 1.5 mL microfuge tube used for plasmid linearization. Solution was pulsevortexed and centrifuged at 12,000 x g for one minute. Using a micropipette, the aqueous
phase was removed and mixed with an equal volume of chloroform in a clean 1.5 mL
microfuge tube. The solution was pulse-vortexed and centrifuged at 12,000 x g for one
minute. Using a micropipette, the aqueous phase was removed and mixed with four
volumes of isopropanol in a clean 1.5 mL microfuge tube. The solution was pulse-vortexed
and centrifuged at 12,000 x g for 10 minutes. The supernatant was decanted from the
DNA pellet. The pellet was rinsed with 70% EtOH, pulse-vortexed, and centrifuged at
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12,000 X g for three minutes. The supernatant was decanted from the DNA pellet. The
pellet was allowed to dry for one hour, then redissolved in 45 pLTE buffer.

3.6 Gel Electrophoretic Purification of Components for Ligation
An electrophoretic gel was prepared with a 2-Log Ladder, EGFP amplicon
(restriction-cut), and linearized pMHAT The gel was produced to separate the EGFP
amplicon from the pMC-EGFP-TIP plasmid used as template DNA to produce the EGFP
amplicon in a PCR reaction. Additionally, this gel was produced to separate the linearized
pMHAT from nicked and supercoiled plasmid that had not been restriction cut, or
linearized. Eliminating these two sources of plasmid would increase the efficiency of our
ligation reaction with the EGFP amplicon and linearized pMHAT components.
The gel was cut twice vertically to create three pieces: cut between'lanes two and
three and cut between lanes six and seven (figure 13). Pieces one and three were stained
with SYBR Green II. Pieces one and three were marked to locate the 1 kb EGFP amphcon
and the 6 kb linearized pMHAT bands. The three pieces of the gel were reassembled. The
unstained portion of the gel was cut to excise the EGFP amplicon and linearized pMHAT
bands with reference to the marked bands on pieces one and three. The excised portions
of the unstained gel were assumed to contain the DNA segments of interest and to not
contain any uncut plasmid or EGFP amplicon template DNA. The two excised portions of
the unstained gel were packaged separately in 3500 Dalton regenerated cellulose dialysis
tubing (Fisher Scientific, cat # 21-152-15). The dialysis tubings were filled with IXTAE
buffer and secured on both ends to prevent leakage. Each tubing was submerged in the
gel electrophoresis apparatus in IX TAE buffer. The gel electrophoresis apparatus was
charged at 60 V for four hours. Each dialysis tubing was removed from the gel
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electrophoresis apparatus. The dialysis tubings 2ind their contents were pulse-vortexed in
separate BD ’ Falcon' 15mL conical polypropylene centrifuge tubes (Fisher Scientific, cat #
05-527-90). Four hundred milliliters were taken from each 15 mL polypropylene centrifuge
tube and added to separate, clean 1.5 mL microfuge tubes with 1 mL isopropanol each.
The 1.5 mL microfuge tubes were centrifuged at 12,000 x g for 10 minutes. The
supernatant was decanted. The microfuge tubes were allowed to dry for one hour. One
hundred milliliters ofTE buffer was added to each dry microfuge tube and the tubes were
pulse-vortexed. The contents of each tube was added to one microfuge tube with 1 mL
isopropanol. The tube was centrifuged at 12,000 x g for 10 minutes. The tube was allowed
to dry for one hour. The DNA pellet was redissolved in 50 pLTE buffer. Gel
electrophoresis was used to confirm quality and concentration of each piece ofDNA
(figure 14). The gel in figure 14 is the last step that has been completed at the time of this
publishing. Ligation of the gel purified pMHAT and EGFP amplicon would conclude step
4 in figure 4.
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Figure 13; Pre-Ligation Gel Electrophoretic DNA Separation: Gel Staining. This figure shows which
areas of the gel are stained to expose separated products. This figure is a graphical representation due to
the inabi lity to expose the entire gel to UV light within the gel imaging apparatus.
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Figure 14: pMHAT and EGFP Insert After Gel Purification. Ml is a 2-log ladder. Lane 1 is restriction
cut EGFP gene amplicon which will be inserted into pMHAT. Lane 2 is linearized pMHAT. The band in
lane 1 aligns with the 10th band of the 2-log ladder which represents 1 kb, the molecular weight of the
EGFP insert. The band in lane 2 aligns with the third band of the 2-log ladder which represents 6 kb, the
molecular weight of pMHAT.
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CONCLUSION

The studying of!OPl in an intact cell line has many capabilities to elucidate and
make easier the studies of protein expression in the drug development industry. Many
new antitumor drugs target TOPl. The use forTOPl expression studies is still in high
demand. When TOPl-targeting antitumor drugs are developed, traditional methods for
quantifying their efficiency are crude, timely, and inconsistent. Additionally,
immunostaining methods for protein expression assays do not allow for real-time protein
expression assays. Likewise, cheaper in vitro TOPl relaxing assays are similarly timeconsuming, erratic, and require a large quantity of highly-purified topoisomerase to
complete a study.
In vitro TOPl expression studies using a stable, immortal cell line have a
significant advantage over current methods. Real-time expression studies decrease the
amount of time and workload required for drug targeting assessments. Secondly, a stable
cell line is able to give consistent results among laboratories, among researchers, and
among trials. Many of the variables inherent to immunohistochemistry are eliminated by
the cell line, namely time uncertainty between harvesting a colony of cells and their
fixation. The need for highly standardized protocols to maintain consistencies in data are
eliminated, from qualities of reagents to personal laboratory methods. Additionally, the
higher level of expertise, the expenses, and the laboratory equipment needed to perform
immunohistochemistry, are replaced by a single cell line. The greater capabilitifes, greater
ease of use, quality of data, and standardization inherent of a natively expressed
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fluorescent TOPI protein in a human cell line, represents the future of antitumor drug
testing and protein expression studies.
At the onset of this project, we anticipated that it could be completed in 2 years.
However, several challenges arose that prevented creating the cell line. Genomic DNA
from the DAOY cell line was used as a template for making the homology arm template
amplicon for pH AT. Progress was delayed several months by the inabihty to produce our
target amplicon, even though our control reactions were working flawlessly. Many
alterations were made to the PCR buffer including the addition and subtraction of various
salts including KCl and MgClj, and other compounds including DMSO and BSA for
polymerase stabilization. After finding one PCR protocol that would produce amphcon,
we found upon sequencing that the fidelity of our amplicon was too poor to continue.
After several PCR buffers were tried, we replaced Tug polymerase. TheFinnzymes
Phusion'“ Flash High-Fidelity DNA Polymerase produced excellent results and allowed the
project to continue. Our amplicon was of high fidelity as sequencing revealed that four
out of four clones contained no mutations.
Another PCR challenge arose during PCR site-directed mutagenesis. Using the
protocol provided by Stratagene, we were still Unable to produce a doubly mutated EGFP
plasmid from pMC-EGFP-TIP. Several polymerases were used, including Taq, PfuTurbo®,
Phusion^” Flash, New England BioLabs™ Deep VentR™, and New England BioLabs^VentR®
polymerases. Other PCR additives including betaine, KCl, MgCh,DMSO,and BSA, were
also tried. We were unable to yield a mutant pMC-TIP-EGFP amplicon. We were able to
produce amplicons of several molecular weights, but gel dectrophoresis showed that we
never produced a discrete band at our target molecular weight of 8 kb. However, a GC
buffer from Finnzymes for the Phusion™ polymerase has not been thoroughly tested here.
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Due to its speed, thermostability, and ability to copy GC-rich templates,Phusion™
polymerase with GC buffer may be able to perform site directed mutagenesis on the EGFP
plasmid. But before testing this polymerase extensively, we attempted another method of
excising the EGFP gene.
A trial was conducted to determine the reason that we could not amplify the oitire
EGFP plasmid. Two PCR reactions for producing two different amphcons from the EGFP
plasmid were used: 1. Opposing primers flanking the EGFP gene would be used to
amplify a 1 kb amplicon. the EGFP gene itself; 2. opposing primers, complementarity to
the two used to amplify the EGFP gene, would be used in a configuration to amplify the
other remaining 7 kb of the plasmid. In this trial, the EGFP gene was amplified but the
rest of the plasmid was not amplified. Consequently, we decided to amplify the EGFP
gene via PCR, use restriction sites within the primers to create sticky ends on the
amplicon, and ligate the sticky amplicon to linearized pMHAT cut with the same enzyme.
However, the ligation reaction has not been completed at the time of this publishing.
There are several reasons that certain amplicons cannot be amplified from
template DNA using published methods. The topologies of chromosomal DNA are not
fully understood. It is known that sections of DNA are more difficult to amplify than
others (i.e. GC-rich segments, heterochromatin and other higher-order structures, other
tertiary structures such as hairpins, cruciforms, etc.). Secondly, it is known that certain
recombinant DNA polymerases are more challenged by certain sections ofDNA than
others. Thirdly, greater lengths of DNA are more challenging amplicons, due to
polymerase degradation and the decreased probability of complete elongation during each
PCR cycle.
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Despite our challenges, several steps toward the completion of the TOPl-EGFP
chimeric protein cell line were completed. Genomic DNA was extracted from the DAOY
cell line. PCR was used to amplify an area of homology starting 1 kb upstream from the
third exon of TOP 1 and ending 1 kb downstream from the third exon. This amplicon was
inserted into a plasmid vector to produce the pHAT plasmid that contains homologous
DNA and will be used to produce homology arms later in the study. Site directed
mutagenesis was used to induce a restriction site into exon 3 ofTOPl ofthepHAT
plasmid, creating the pMHAT plasmid. Several attempts of inserting the EGFP gene into
the pMH AT plasmid were made. This gene insertion was not completed at the time of this
publishing.
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